AUA 2025: Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with mRCC
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with metastatic renal cell carcinoma.